Wang Heting, Duan Hua, Chen Shiyin, Luo Yong, Zhang Yuan, Liu Qingsong, Zhang Xiyu
Hospital of Chengdu University of Traditional Chinese Medicine.
Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan Province, P.R. China.
Medicine (Baltimore). 2020 Aug 7;99(32):e21510. doi: 10.1097/MD.0000000000021510.
The prevalence of gout is increasing worldwide, and the symptoms of acute arthritis appearing in gout patients seriously affect the quality of life. The pain and functional limitation caused by acute gouty arthritis (AGA) bring great pain to patients. At present, mainstream drugs have problems such as poor efficacy and side effects. Traditional Chinese medicine has extensive clinical experience in the prevention and treatment of gout, and it also shows clear advantages in the treatment of AGA. Clinical studies have confirmed that si-miao-san decoction (SMSD), a traditional Chinese medicine decoction, can improve the clinical symptoms and signs of AGA patients. Therefore, we will conduct a systematic review to clarify the effectiveness and safety of SMSD for AGA.
We will search different database from the built-in to October 2020. The electronic database includes PubMed, Embase, Cochrane Library, Web of Science, CNKI, WanFang, VIP, and CBM. At the same time, we will also search for clinical registration tests and gray literatures. This study only screened clinical randomized controlled trials (RCT) for SMSD for AGA. The 2 researchers independently conducted literature selection, data extraction, and quality assessment. Dichotomous data are represented by relative risk (RR), continuous data are represented by mean difference (MD) or standard mean deviation (SMD), and the final data are fixed effect model (FEM) or random effect model (REM), depending on whether it exists heterogeneity. The main outcomes are clinical efficacy, including pain score, joint function, and degree of swelling. The secondary outcomes include: blood uric acid (BUA), C-reactive protein (CRP), and erythrocyte sedimentation rate (ESR). Finally, a meta-analysis was conducted through Review Manager software version 5.3.
This study will conduct a comprehensive analysis based on the currently released Si-Miao-San data for the treatment of AGA and provide high-quality evidence of clinical efficacy and safety.
This systematic review aims to provide new options for SMSD treatment of AGA in terms of its efficacy and safety.
The review is based solely on a secondary study of published literatures and does not require ethics committee approval. Its conclusion will be disseminated in conference papers, magazines, or peer-reviewed journals.
INPLASY202040163.
痛风在全球的患病率正在上升,痛风患者出现的急性关节炎症状严重影响生活质量。急性痛风性关节炎(AGA)引起的疼痛和功能受限给患者带来极大痛苦。目前,主流药物存在疗效不佳和副作用等问题。中医在痛风的防治方面有丰富的临床经验,在AGA的治疗中也显示出明显优势。临床研究证实,中药方剂四妙散(SMSD)可改善AGA患者的临床症状和体征。因此,我们将进行一项系统评价,以阐明SMSD治疗AGA的有效性和安全性。
我们将检索自建库至2020年10月的不同数据库。电子数据库包括PubMed、Embase、Cochrane图书馆、Web of Science、中国知网、万方、维普和中国生物医学文献数据库。同时,我们还将检索临床注册试验和灰色文献。本研究仅筛选针对SMSD治疗AGA的临床随机对照试验(RCT)。两名研究人员独立进行文献筛选、数据提取和质量评估。二分数据用相对危险度(RR)表示,连续数据用均数差(MD)或标准化均数差(SMD)表示,最终数据采用固定效应模型(FEM)或随机效应模型(REM),具体取决于是否存在异质性。主要结局为临床疗效,包括疼痛评分、关节功能和肿胀程度。次要结局包括:血尿酸(BUA)、C反应蛋白(CRP)和红细胞沉降率(ESR)。最后,通过Review Manager 5.3版软件进行荟萃分析。
本研究将基于目前已发表的四妙散治疗AGA的数据进行综合分析,并提供临床疗效和安全性的高质量证据。
本系统评价旨在从疗效和安全性方面为SMSD治疗AGA提供新的选择。
本评价仅基于已发表文献的二次研究,无需伦理委员会批准。其结论将在会议论文、杂志或同行评审期刊上发表。
INPLASY注册号:INPLASY202040163。